The Authors describe their own experience of functioning and nonfunctioning tumors of the adrenal gland. In two cases the neoplasm was an adrenal adenoma, one causing a Cushing syndrome, the other clinically asymptomatic and associated with renal tuberculosis. In two patients the neoplasm was a clinically unsuspected pheochromocytoma and in one case it proved to be a malignant tumor.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs).
Pituitary
January 2025
Division of Endocrinology, Santiago de Compostela University and Ciber OBN, Santiago, Spain.
Purpose: A recent update of consensus guidelines for the management of Cushing's disease (CD) included indications for medical therapy. However, there is limited evidence regarding their implementation in clinical practice. This study aimed to evaluate current medical therapy approaches by expert pituitary centers through an audit conducted to validate the criteria of Pituitary Tumors Centers of Excellence (PTCOEs) and provide an initial standard of medical care for CD.
View Article and Find Full Text PDFA rare case of lipomatous ganglioneuroma of the adrenal gland.
Urol Case Rep
March 2025
Department of Urology, Liverpool Hospital, Liverpool, NSW, Australia.
Lipomatous ganglioneuroma's are exceedingly rare benign tumours. They originate from the neuroepithelium along the sympathetic ganglia. These rare tumours have been reported generally in the posterior mediastinum and retroperitoneum.
View Article and Find Full Text PDFChronic Stress Mediates Inflammatory Cytokines Alterations and Its Role in Tumorigenesis.
J Inflamm Res
January 2025
Department of Otorhinolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
Introduction: Prolonged psychological stress is closely associated with cancer due to its role in promoting the release of stress hormones through the sustained activation of the sympathetic-adrenal-medullary system. These hormones interact with receptors on inflammatory cells, leading to the activation of key signaling pathways, including the transcription factors signal transducer and activator of transcription 3 (STAT-3) and kappa-light-chain-enhancer of activated B cells (NF-κB). These factors drive the production of pro-inflammatory substances, such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), which can influence the initiation and progression of cancer.
View Article and Find Full Text PDFAberrant Cytoplasmic INSM1 Expression in Erythroid Cells: A Potential Diagnostic Pitfall Versus Neuroendocrine Neoplasms.
Int J Surg Pathol
January 2025
Department of Pathology, Stanford Medical Center, Stanford, CA, USA.
Insulinoma-associated protein 1 (INSM1) is a relatively new immunostain used in the diagnostic assessment of tumors with neuroendocrine differentiation. While INSM1 positivity has been described in some non-neuroendocrine neoplasms, reactivity in red blood cells (RBCs) has only been anecdotally noted in one prior study without description of the degree/extent of staining. INSM1 staining in nucleated erythroid precursors has not been previously reported.
View Article and Find Full Text PDFMore than meets the eye: predicting adrenocortical carcinoma outcomes with pathomics.
Eur J Endocrinol
January 2025
Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong, PR China.
Background: Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with high recurrence rates and poor prognosis. Current prognostic models are inadequate, highlighting the need for innovative diagnostic tools. Pathomics, which utilizes computer algorithms to analyze whole-slide images, offers a promising approach to enhance prognostic models for ACC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!